Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBonanad, Clara
dc.contributor.authorRaposeiras-Roubin, Sergio
dc.contributor.authorGarcía-Blas, Sergio
dc.contributor.authorNuñez-Gil, Iván J.
dc.contributor.authorVergara-Uzcategui, Carlos Eduardo
dc.contributor.authorDíez-Villanueva, Pablo
dc.contributor.authorBañeras Rius, Jordi
dc.contributor.authorBadia Molins, Clara
dc.date.accessioned2022-08-11T09:24:58Z
dc.date.available2022-08-11T09:24:58Z
dc.date.issued2022-03-17
dc.identifier.citationBonanad C, Raposeiras-Roubin S, García-Blas S, Núñez-Gil I, Vergara-Uzcategui C, Díez-Villanueva P, et al. Evaluation of the Use of Dual Antiplatelet Therapy beyond the First Year after Acute Coronary Syndrome. J Clin Med. 2022 Mar 17;11(6):1680.
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/11351/7988
dc.descriptionAcute coronary syndrome; Dual antiplatelet therapy; Ischemic risk
dc.description.abstractClinical practice guidelines recommend extending dual antiplatelet therapy (DAPT) beyond 1 year after acute coronary syndrome (ACS) in patients with high ischemic risk and without high bleeding risk. The aim of this study was to identify variables associated with DAPT prolongation in a cohort of 1967 consecutive patients discharged after ACS without thrombotic or hemorrhagic events during the following year. The sample was stratified according to whether DAPT was extended beyond 1 year, and the factors associated with this strategy were analyzed. In 32.2% of the patients, DAPT was extended beyond 1 year. Overall, 770 patients (39.1%) were considered candidates for extended treatment based on PEGASUS criteria and absence of high bleeding risk, and DAPT was extended in 34.4% of them. The presence of a PEGASUS criterion was associated with extended DAPT in the univariate analysis, but not history of bleeding or a high bleeding risk. In the multivariate analysis, a history of percutaneous coronary intervention (odds ratio (OR) = 1.8, 95% confidence interval (CI) 1.4–2.4), stent thrombosis (OR = 3.8, 95% CI 1.7–8.9), coronary artery disease complexity (OR = 1.3, 95% CI 1.1–1.5), reinfarction (OR = 4.1, 95% CI 1.6–10.4), and clopidogrel use (OR = 1.3, 95% CI 1.1–1.6) were significantly associated with extended use. DAPT was extended in 32.2% of patients who survived ACS without thrombotic or hemorrhagic events. This percentage was 34.4% when the candidates were analyzed according to clinical guidelines. Neither the PEGASUS criteria nor the bleeding risk was independently associated with this strategy.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Clinical Medicine;11(6)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMalalties coronàries - Tractament
dc.subjectPlaquetes sanguínies - Trastorns
dc.subject.meshAcute Coronary Syndrome
dc.subject.mesh/therapy
dc.subject.meshPlatelet Aggregation Inhibitors
dc.titleEvaluation of the Use of Dual Antiplatelet Therapy beyond the First Year after Acute Coronary Syndrome
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jcm11061680
dc.subject.decssíndrome coronario agudo
dc.subject.decs/terapia
dc.subject.decsinhibidores de la agregación plaquetaria
dc.relation.publishversionhttps://doi.org/10.3390/jcm11061680
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bonanad C, García-Blas S] Cardiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain. Department of Cardiology, INCLIVA Biomedical Research Institute, Valencia, Spain. Department of Medicine, University of Valencia, Valencia, Spain. [Raposeiras-Roubin S] Cardiology Department, Hospital Universitario Álvaro Cunqueiro de Vigo, Vigo, Spain. [Núñez-Gil I, Vergara-Uzcategui C] Cardiology Department, Hospital Clínico San Carlos, Madrid, Spain. [Díez-Villanueva P] Cardiology Department, Hospital Universitario de la Princesa, Madrid, Spain. [Bañeras J, Badía Molins C] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35330004
dc.identifier.wos000774973900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record